Drug intelligence / Profile preview

IDE574

Development stage: Phase 1
Lead developer: IDEAYA Biosciences
Modality: Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

IDE574 is a first-in-class dual inhibitor of the histone lysine acetyltransferases KAT6 and KAT7, being developed by IDEAYA Biosciences as an antineoplastic agent. The drug targets the KAT6A, KAT6B, and KAT7 proteins to inhibit their activity. These enzymes are involved in chromatin remodeling and gene expression regulation through acetylation of histone proteins. By inhibiting these targets, IDE574 aims to disrupt oncogenic transcriptional programs in cancer cells. As of May 2025, it is classified as a new molecular entity and is in preclinical development for solid tumors[1][3].

Targets

KAT7 (Lysine acetyltransferase 7)KAT6A (Lysine acetyltransferase 6A)KAT6B (Histone acetyltransferase KAT6B)

Beyond the preview

Go deeper on IDE574.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDE574.

Explore the full profile